research High-confidence cancer patient stratification through multiomics investigation of DNA repair disorders
CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.
Search
for
Sort by
Research
480-510 / 1000+ results 
research 6450 Leydig Cell Tumor: A Rare Cause of Post-menopausal Hyperandrogenism
Leydig cell tumors can cause high testosterone and symptoms in postmenopausal women, and removing them improves symptoms.
research 5α-Reductase inhibitors in androgenetic alopecia
research Ovarian intratumoral 21-hydroxylase deficiency in a postmenopausal hirsute woman
A postmenopausal woman's masculine symptoms improved after surgery for a hormone-producing ovarian tumor.
research The effect of treatment with an LH-RH agonist (Buserelin) on gonadal activity growth and bone maturation in children with central precocious puberty
Buserelin safely and effectively suppresses early puberty, potentially improving final height.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research Formestane Preferred as Second-Line Therapy in Advanced Breast Cancer
Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
![The Synthesis of (−)-4-Methyl-8-Chloro-Trans-1,2,3,4,4a,5,6,10b-Octahydrobenzo-[f]-Quinolin-3-One-[3-14C] (LY300502-14C) via a Circuitous Route](/images/research/73bab8dc-bdf0-45e3-8ef7-73d0d4b93cb1/small/21074.jpg)
research The synthesis of (−)-4-methyl-8-chloro-trans-1,2,3,4,4a,5,6,10b-octahydrobenzo-[f]-quinolin-3-one-[3-14C] (LY300502-14C]) via a circuitous route
Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.
research Hiperandrogenismo avanzado en una mujer postmenopáusica: Caso clínico
A postmenopausal woman's high testosterone levels and symptoms improved after removing a tumor from her ovary.
research Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
research Leydig cell hyperplasia as a cause of virilization in a postmenopausal woman: A case report
Leydig cell hyperplasia can cause virilization in postmenopausal women and is treatable with surgery.
research Risk of Estrogen-Driven Malignancies in Females on 5-alpha Reductase Inhibitors
Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
research The Antiandrogens
research Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
research POSTMENOPAUSAL VIRILIZATION
Thorough evaluation is crucial for postmenopausal women with virilization to detect rare ovarian tumors.
research Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women
The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
research Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is effective long-term for treating alopecia areata in teens.
research Determination of rat 5α-reductase type 1 isozyme activity and its inhibition by novel steroidal oxazolines
New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
research INSULIN-LOWERING MEDICATIONS IN POLYCYSTIC OVARY SYNDROME
Insulin-lowering medications show promise for PCOS symptoms but can't be the main treatment yet due to limited long-term research.
research Androgen Therapy for Postmenopausal Women; What is New?
research 0282 Effect of systemic immunomodulators on incidence of alopecia areata: A retrospective cohort study
Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research OR20-01 Machine Learning-based Steroid Metabolome Analysis In Women With Polycystic Ovary Syndrome Reveals Three Distinct Androgen Excess Subtypes With Different Metabolic Risk Profiles.
Machine learning identified three unique subtypes of androgen excess in women with PCOS, each with different metabolic risks.
research Lokaltherapie der Alopecia androgenetica mit 17α-Östradiol
17α-estradiol lotion can reduce hair loss but doesn't promote new hair growth.
research Clinical Observation of Polycystic Ovary Syndrome Treatment with Resveratrol
Resveratrol improved hormone levels, menstrual cycles, hair loss, and ovarian function in PCOS patients.
research FINASTERIDE (PLUS ORAL CONTRACEPTIVE PILL) VS METFORMIN IN TREATMENT OF POLYCYSTIC OVARY SYNDROME-RELATED INFERTILITY: A PROSPECTIVE RANDOMIZED TRIAL
research The α-Lipoic acid derivative sodium zinc dihydrolipoylhistidinate reduces chemotherapy-induced alopecia in a rat model: A pilot study
A substance called sodium zinc dihydrolipoylhistidinate can significantly reduce hair loss caused by chemotherapy in rats.
research Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome
MPA improved hormonal imbalances and acne in women with PCOS without affecting metabolism.
research Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
research In Silico Screening of DrugBank Compounds as Potential Inhibitors for Human Steroid 5α-Reductase 2 for Androgen-Related Diseases
Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.